AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
News|Articles|July 2, 2009
UK Strengthens Drug Supply Chain
Author(s)Stephanie Sutton
The UK's Medicines and Healthcare Regulatory Agency (MHRA) has published the outcome of a consultation on measures to strengthen the country's drug supply chain.
Advertisement
The UK's Medicines and Healthcare Regulatory Agency (MHRA) has published the outcome of a consultation on measures to strengthen the country's drug supply chain. The three-month consultation also sought opinions on the EC's proposals to amend
There was broad support among respondents for measures intended to increase confidence in a Wholesale Dealer's license, as well as provisions aimed at raising the professional status of the Responsible Person by introducing a Code of Practice against which the Responsible Person can be judged. A number of comments were also received by the agency regarding provisions aimed at pharmacies.
Regarding the storage and transit of drugs, there was support for better controls over transit arrangements and audit trails; however, concerns were raised about how this could be applied to the wide range of transport suppliers currently used, and whether the introduction of proposals for licensing, auditing, and inspection would cause some suppliers to refuse to transport medicines. In reply, the MHRA said that it would consult logistic provider organizations when taking any proposals forward.
The consultation also discussed proposals regarding criminal sanctions for offenses associated with the counterfeiting of medicines. Respondents believe that current penalties are limited in scope and do not provide any deterrent, and that there is a need to introduce a specific counterfeiting offense. This is something the MHRA has said that it will explore further.
The
Stephanie Sutton is an assistant editor at Pharmaceutical Technology Europe.
Advertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
3
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
4
NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains
5